Boundless Bio, Inc.

Cogent Bio Presents Bezuclastinib Data Highlighting Long-Term Benefits in Non-Advanced Systemic Mastocytosis

4 months ago

• Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients. • The poster highlights efficacy and safety results from the ongoing SUMMIT trial in adult NonAdvSM patients receiving 100mg of bezuclastinib. • Cogent anticipates top-line results from the SUMMIT trial in July 2025 and plans to submit an NDA for bezuclastinib by the end of 2025. • Expanded Access Programs for bezuclastinib are expected to launch in the U.S. in Q1 2025 for Systemic Mastocytosis and Gastrointestinal Stromal Tumors patients.

Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments

4 months ago

• Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions. • Several companies, including Intellia Therapeutics and IGM Biosciences, are cutting a significant portion of their workforce to focus on key programs and extend cash runways. • These workforce reductions are often accompanied by discontinuation of certain drug development programs and a shift in strategic focus towards core assets. • The layoffs reflect a broader trend in the industry as companies adapt to evolving market dynamics and prioritize efficiency and long-term sustainability.

Bristol Myers Faces Lawsuit from Padlock Therapeutics Investors Over Milestone Payment Dispute

5 months ago

• Padlock Therapeutics investors, including Atlas Venture, have filed a lawsuit against Bristol Myers Squibb over alleged refusal to pay milestone payments from a $600 million acquisition deal. • The dispute centers around a 2016 acquisition where Bristol Myers paid $150 million upfront and promised an additional $450 million in milestone payments to Padlock shareholders. • Industry experts warn this dispute could have significant implications for the biotech sector, as milestone payment structures are fundamental to acquisition deals in the industry.

Boundless Bio Prioritizes BBI-355 and New ecDTx Program, Discontinues BBI-825 Development

5 months ago

• Boundless Bio will not advance BBI-825 into Part 2 of the STARMAP trial due to pharmacokinetic data and the evolving treatment landscape. • The company is prioritizing BBI-355, with initial clinical data expected in the second half of 2025, and a third ecDTx program. • Boundless Bio anticipates nominating a development candidate for its third ecDTx program by mid-2025 and submitting an IND in H1 2026. • Leadership changes include the departure of the CMO and CBO, with James L. Freddo, M.D., appointed as Interim CMO.

Targeting Rogue DNA Loops Shows Promise in Treating Aggressive Cancers

7 months ago

• Researchers identified extrachromosomal DNA (ecDNA) in 17.1% of tumors across 39 cancer types, highlighting its role in tumor growth and treatment resistance. • The study suggests that ecDNA fragments carry cancer-driving genes and suppress the immune system, contributing to tumor resilience against therapies. • A CHK1 inhibitor, developed by Boundless Bio, demonstrated potential in reducing tumors and preventing resistance when combined with traditional anti-cancer drugs in mice. • Scientists believe targeting ecDNA could offer a new therapeutic avenue for aggressive cancers by exploiting vulnerabilities created by this unique type of DNA.

Unlocking Cancer's Code: Scientists Target DNA Circles for Novel Therapies

7 months ago

• Researchers have discovered that ecDNAs, circular DNA structures in cancer cells, can contain enhancers that drive gene expression on other ecDNAs, promoting cancer cell growth. • Unlike chromosomes, ecDNA transcription continues during cell division, causing advantageous combinations of ecDNAs to segregate together, giving cancer cells a survival advantage. • Blocking the checkpoint protein CHK1 leads to the death of ecDNA-containing tumor cells and tumor regression in mice, suggesting a new therapeutic approach. • A CHK1 inhibitor is currently in early phase clinical trials for cancers with multiple copies of oncogenes on ecDNAs, showing promise for targeted cancer treatment.

SOPHiA GENETICS' ecDNA Assay Validated for Boundless Bio's Clinical Trial

9 months ago

• SOPHiA GENETICS and Boundless Bio collaborate with Precision for Medicine to validate a novel clinical trial assay for detecting extrachromosomal DNA (ecDNA). • The ecDNA Solution (ECS) algorithm identifies patients with ecDNA-amplified tumors for Boundless Bio's POTENTIATE Phase 1/2 study of BBI-355. • Precision for Medicine adapts its diagnostic workflow to integrate with the SOPHiA DDM™ Platform, enhancing patient selection for clinical trials. • The collaboration aims to expedite clinical trial enrollment and support the development of new ecDNA-directed therapies for cancer patients.